LOW-DOSE CONTINUOUS INDOMETHACIN IN EARLY DAYS OF AGE REDUCE THE INCIDENCE OF SYMPTOMATIC PATENT DUCTUS ARTERIOSUS WITHOUT ADVERSE EFFECTS

ABSTRACT

We conducted a comparative study to evaluate whether the low-dose continuous indomethacin therapy in the early days of age would reduce incidence of the symptomatic patent ductus arteriosus (PDA) without the adverse effects. Thirty-seven infants were in the historical comparison group, and 39 infants were given low-dose indomethacin continuously (0.004 mg/kg/h) from 6-12 postnatal hours until the recognition of closing PDA. Low-dose continuous indomethacin significantly decreased the incidence of symptomatic PDA at 5 days of age (p < 0.01) as compared with the historical comparison group. There was no episode of decreasing urinary output and necrotizing enterocolitis in the indomethacin group. We conclude that the low-dose continuous indomethacin therapy results in decreasing the incidence of symptomatic PDA without significant adverse reactions.

KEYWORD

Low-dose continuous indomethacin - patent ductus arteriosus - adverse effects

REFERENCES

• 1 Fuziwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease.  Lancet . 1980;  1 55-59
• 2 Rojas M A, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease.  J Pediatr . 1995;  126 605-610
• 3 Mahony L, Caldwell R L, Girod D A, Hurwitz R A, Jansen R D, Lemons J A, Schreiner R L. Indomethacin therapy on the first day of life in infants with very low birth weight.  J Pediatr . 1985;  106 801-805
• 4 Hanigan W C, Kennedy G, Roemisch F, Anderson R, Cusack T, Powers W. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates.  J Pediatr . 1988;  112 941-947
• 5 Bandstra E S, Montalvo B M, Goldberg R N. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants.  Pediatrics . 1988;  82 533-542
• 6 Bada H S, Green R S, Pourcyrous M. Indomethacin reduces the risks of severe intraventricular hemorrhage.  J Pediatr . 1989;  115 631-637
• 7 Ment L R, Duncan C C, Ehrenkranz R A. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates.  J Pediatr . 1988;  112 948-955
• 8 Ment L R, Oh W, Ehrenkranz R A. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial.  J Pediatr . 1994;  123 951-955
• 9 Ment L R, Oh W, Ehrenkranz R A. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial.  Pediatrics . 1994;  93 543-550
• 10 Colditz P, Murphy D, Rolfe P, Wilkinson A R. Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates.  Arch Dis Child . 1989;  64 8-12
• 11 Edwards A D, Wyatt J S, Richardson C. Effects of indomethacin on cerebral haemodynamics in very preterm infants.  Lancet . 1990;  335 1451-1495
• 12 Austin N C, Pairaudeau P W, Hames T K, Hall M A. Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants.  Arch Dis Child . 1991;  67 851-854
• 13 Hammerman C, Glaser J, Schimmel M S, Ferber B, Kaplan M, Eidelman A I. Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity.  Pediatrics . 1995;  95 244-248
• 14 Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.  J Pediatr . 1997;  131 549-554
• 15 Yanowitz T D, Yao A C, Werner J C, Pettigrew K D, Oh W, Stonestreet B S. Effects of prophylactic low-dose indomethacin on hemodynamics in very low birth weight infants.  J Pediatr . 1998;  132 28-34
• 16 Papile L A, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm.  J Pediatr . 1978;  110 921-928
• 17 Walsh M, Kliegman R. Necrotizing enterocolitis: treatment based on staging criteria.  Pediatr Clin North Am . 1986;  33 179-201
• 18 Piecuch R E, Leonard C H, Cooper B A, Sehring S A. Outcome of extremely low birth weight infants (500 to 999 grams) over a 12-year period.  Pediatrics . 1997;  100 633-639
• 19 Marshall D D, Kotelchuck M, Young T E, Bose C L, Kruyer L, O'Shea T M. Risk factor for chronic lung disease in surfactant era: a North Carolina population-based study of very low birth weight infants.  Pediatrics . 1999;  104 1345-1350
• 20 Cotton R B, Stahlman M T, Bender H W, Graham T P, Catterton W Z, Konvar I. Randomized trial of early closure of symptomatic patent ductus arteriosus in a small preterm infants.  J Pediatr . 1978;  93 647-651
• 21 Merritt T A, Harris J P, Roghmann K. Early closure of patent ductus arteriosus in very-low-birth-weight infants: a controlled trial.  J Pediatr . 1981;  99 281-286
• 22 Brown E R. Increased risk of bronchopulmonary dysplasia in infant with patent ductus arteriosus.  J Pediatr . 1979;  95 865-866
• 23 Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation.  Biol Neonate . 1980;  38 96-105
• 24 Stefano J L, Abbasi S, Pearlman S A, Spear M L, Esterly K L, Bhuthani V K. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome: effects on pulmonary compliance and ventilation.  Am Rev Respir Dis . 1991;  143 236-239
• 25 Gonzalez A, Sosenko I RS, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less.  J Pediatr . 1996;  128 470-478